Using CRISPR technology to enhance CAR-T cells
Patrick Hwu shared on X:
“How do we make more effective CAR-T cells? The Marco Ruella lab recently published work demonstrating that using CRISPR technology to knock out the CD5 gene in T-cells enhanced their ability to expand, persist, and kill tumor cells. This will be an exciting strategy to apply to human clinical trials.
‘CD5 deletion enhances the antitumor activity of adoptive T cell therapies‘
Authors: Ruchi P. Patel, Guido Ghilardi, Yunlin Zhang, Yi-Hao Chiang, Wei Xie, Puneeth Guruprasad, Ki Hyun Kim, Inkook Chun, Mathew G. Angelos, Raymone Pajarillo, Seok Jae Hong, Yong Gu Lee, Olga Shestova, Carolyn Shaw, Ivan Cohen, Aasha Gupta, Trang Vu, Dean Qian, Steven Yang, Aditya Nimmagadda, Adam E. Snook, Nicholas Siciliano, Antonia Rotolo, Arati Inamdar, Jaryse Harris, Ositadimma Ugwuanyi, Michael Wang, Alberto Carturan, Luca Paruzzo, Linhui Chen, Hatcher J. Ballard, Tatiana Blanchard, Chong Xu, Mohamed Abdel-Mohsen , Khatuna Gabunia, Maria Wysocka, Gerald P. Linette, Beatriz Carreno, David M. Barrett, David T. Teachey, Avery D. Posey, Daniel J. Powell Jr., C. Tor Sauter, Stefano Pileri, Vinodh Pillai, John Scholler, Alain H. Rook, Stephen J. Schuster, Stefan K. Barta, Patrizia Porazzi, Marco Ruella. ”
Source: Patrick Hwu/X
Dr. Patrick Hwu, MD, currently serves as the President and CEO of Moffitt Cancer Center. With a focus on understanding the dynamics between tumors and the immune system, Dr. Hwu’s research has been pivotal in advancing gene-modified T cell therapy. He notably contributed seminal work on the development of the first chimeric antigen receptor aimed at combating cancer. His research portfolio extends to vaccines, adoptive T-cell therapies, and mechanisms of immune resistance.
Before joining, Dr. Hwu held numerous leadership roles at The University of Texas MD Anderson Cancer Center for over 17 years. Notably, he served as the inaugural Chairman of the Department of Melanoma Medical Oncology in 2003, as well as the Associate Director of the Center for Cancer Immunology Research. Additionally, he chaired the Department of Sarcoma Medical Oncology, demonstrating his commitment to advancing cancer treatment and research.